Summary CellCentric has raised $220 million in a Series D financing to advance inobrodib, an oral p300/CBP inhibitor for multiple myeloma, supporting ongoing Phase 2 studies and planned Phase 3 development. What Happened The financing will fund late-stage clinical development…
Company Takeda Pharmaceutical (Osaka / Cambridge, MA) Event Type Phase 2/3 pivotal trial topline results — primary endpoint met Modality Plasma-derived immunoglobulin SC with recombinant human hyaluronidase Target IgG replacement / immune reconstitution Indication Primary Immunodeficiency Disease (PID) — adults…
Summary Protagonist Therapeutics has opted out of its 50:50 US profit-sharing agreement with Takeda for rusfertide, granting Takeda full US commercial rights in exchange for up to $475 million in near-term payments and substantial downstream milestones and royalties. What Happened…
Summary Eli Lilly has entered a definitive agreement to acquire Ajax Therapeutics in a deal worth up to $2.3 billion to secure AJ1-11095, a first-in-class Type II JAK2 inhibitor for myelofibrosis and polycythemia vera, positioning Lilly in the next-generation JAK…
Summary Intellia Therapeutics reported that its in vivo CRISPR gene-editing therapy, lonvoguran ziclumeran (lonvo-z), met its Phase 3 primary endpoint in hereditary angioedema, reducing swelling attacks by 87% versus placebo and advancing toward FDA submission. What Happened Intellia announced positive…
Summary CorMedix reported positive Phase 3 results from the ReSPECT trial for rezafungin (REZZAYO), demonstrating non-inferiority to standard antimicrobial regimens for prevention of invasive fungal disease (IFD) in allogeneic hematopoietic stem cell transplant (allo-HSCT) patients. What Happened The Phase 3…
Summary Compass Therapeutics reported that its DLL4xVEGF-A bispecific antibody, tovecimig, failed to meet the overall survival (OS) endpoint in a Phase 2/3 trial in biliary tract cancer, despite showing a statistically significant progression-free survival (PFS) benefit. What Happened In the…
Summary Regeneron has entered into a ‘most favored nation’ (MFN) drug-pricing agreement with the White House, aligning certain drug prices with Medicaid benchmarks. The move reflects increasing policy pressure on pharmaceutical pricing rather than a scientific or clinical development. What…
Summary Pfizer has discontinued a Phase 1 immunostimulatory drug-conjugate program in oncology, highlighting challenges in developing next-generation targeted delivery modalities. What Happened Pfizer ended development of an early-stage immunostimulatory drug-conjugate candidate that had been in Phase 1 testing. The program…
Summary Merck has entered a ~$1 billion enterprise agreement with Google Cloud to expand use of AI across its R&D and operational infrastructure, marking a major investment in AI-enabled drug development capabilities. What Happened Merck signed a long-term deal with…
